How GLP-1s tanked and reshaped the medtech stock market

Promising clinical trial results on glucagon-like peptide 1 agonists (GLP-1s) created a seismic shift in the medtech stock market.

Related Keywords

United States ,China ,Boston ,Massachusetts ,American ,Massdevice Medtech ,Johnson Medtech ,Kevin Lobo ,Depuy Synthes ,Myriam Curet ,Zimmer Biomet ,Relievant Medsystems ,Mike Matson ,Fukuda Denshi ,Nihon Kohden ,Novo Nordisk Wegovy ,Richard Newitter ,Medtronic ,Google ,Ge Healthcare ,Barco ,Needham Co ,Respironics ,Caption Health ,Boston Scientific ,Novo Nordisk ,American Heart Association ,Philips ,American Diabetes Association ,Medical Design ,Medtech Big ,Dow Jones Industrial ,Truist Securities ,David Rescott ,Intuitive Surgical ,Surgical Chief Medical Officer ,Cardiovascular Systems ,Bigfoot Biomedical ,Royal Philips ,Globus Medical ,Virtual Care Management ,Mayo Clinic ,Vscan Air ,